Novo Nordisk and Fournier Pharma Sign Co-Marketing Agreement for Repaglinide in Europe
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 36 (Table of Contents)
Published: 3 May-2003
DOI: 10.3833/pdr.v2003.i36.910 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Novo Nordisk entered into a deal with Fournier Pharma to co-market its Repaglinide drug in Europe...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS